AU2017381587A1 - Novel cannabinoid compositions and methods of treating pediatric epilepsy - Google Patents

Novel cannabinoid compositions and methods of treating pediatric epilepsy Download PDF

Info

Publication number
AU2017381587A1
AU2017381587A1 AU2017381587A AU2017381587A AU2017381587A1 AU 2017381587 A1 AU2017381587 A1 AU 2017381587A1 AU 2017381587 A AU2017381587 A AU 2017381587A AU 2017381587 A AU2017381587 A AU 2017381587A AU 2017381587 A1 AU2017381587 A1 AU 2017381587A1
Authority
AU
Australia
Prior art keywords
cbd
composition
day
thc
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017381587A
Other languages
English (en)
Inventor
Caleb Joshua Eades
Catherine JACOBSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tilray Brands Inc
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of AU2017381587A1 publication Critical patent/AU2017381587A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
AU2017381587A 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating pediatric epilepsy Abandoned AU2017381587A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436861P 2016-12-20 2016-12-20
US62/436,861 2016-12-20
PCT/IB2017/001683 WO2018115962A1 (en) 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating pediatric epilepsy

Publications (1)

Publication Number Publication Date
AU2017381587A1 true AU2017381587A1 (en) 2019-06-20

Family

ID=61028091

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017381587A Abandoned AU2017381587A1 (en) 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating pediatric epilepsy

Country Status (12)

Country Link
US (1) US20200215022A1 (https=)
EP (1) EP3558297A1 (https=)
JP (2) JP2020514282A (https=)
KR (1) KR20190099221A (https=)
AU (1) AU2017381587A1 (https=)
BR (1) BR112019012776A2 (https=)
CA (1) CA3046320A1 (https=)
CL (1) CL2019001668A1 (https=)
CO (1) CO2019006911A2 (https=)
MX (1) MX2019007496A (https=)
PE (1) PE20200338A1 (https=)
WO (1) WO2018115962A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
CA3130763A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
GB2598922A (en) 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023047308A1 (en) * 2021-09-22 2023-03-30 Avicanna Inc. Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
MX385464B (es) * 2014-12-12 2025-03-18 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
EP3253375B1 (en) * 2016-02-11 2019-04-10 Gelpell AG Oral solid cannabinoid formulations, methods for producing and using thereof

Also Published As

Publication number Publication date
MX2019007496A (es) 2019-10-30
WO2018115962A1 (en) 2018-06-28
CO2019006911A2 (es) 2019-08-30
EP3558297A1 (en) 2019-10-30
PE20200338A1 (es) 2020-02-14
CL2019001668A1 (es) 2019-09-06
JP2020514282A (ja) 2020-05-21
JP2023001138A (ja) 2023-01-04
BR112019012776A2 (pt) 2019-12-10
CA3046320A1 (en) 2018-06-28
KR20190099221A (ko) 2019-08-26
US20200215022A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
JP2023001138A (ja) 新規カンナビノイド組成物および使用方法
AU2019297198B2 (en) Composition and method for treating pain
EP3215148B1 (en) Use of low dose of tetrahydrocannabinol for the treatment of cognitive decline in elderly patients
US20200276155A1 (en) Composition and method for treating autism
WO2019224824A1 (en) Cannabis-based compositions for the treatment of autistic spectrum disorders
JP2019510060A (ja) 胃腸管の炎症性疾患の治療のためのカンナビノイドおよびカンナビスベースの組成物および方法
US20240024340A1 (en) Compositions and Methods For Treating Migraine
AU2021215262A1 (en) Composition and method for treating chronic pain
WO2020188568A1 (en) Methods and compositions for treating autism spectrum disorder and associated disorders
WO2020183455A1 (en) Cannabinoid combinations for treating low back pain
US20210290592A1 (en) Composition and method for opioid sparing
RS65144B1 (sr) Postupak za lečenje prader-vilijevog sindroma
KR20080021139A (ko) 편두통을 위한 드로나비놀 치료
Gupta et al. Valbenazine for the treatment of adults with tardive dyskinesia
CA3200651A1 (en) Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
WO2021077108A1 (en) Method of treating autism
US20230338397A1 (en) Composition comprising cannabinoids, and/or terpens, and methods of using same
WO2020188569A1 (en) Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
AU2021106137A4 (en) Composition and method for treating chronic pain
AU2024324600A1 (en) Composition of cannabinoid extract of cw1as1 for the treatment of autism and associated symptoms
KR20260049238A (ko) 만성 요통, 만성 비특이적 요통, 골관절염 또는 기타 만성 근골격 통증 병태를 포함하는 만성 근골격 통증의 치료 및/또는 예방에 사용하기 위한 델타-9-테트라하이드로칸나비놀 및 테르펜을 포함하는 조성물
Harshit Gupta et al. Valbenazine for the Treatment of Adults with Tardive Dyskinesia
Allen et al. Does phentermine use for weight loss have significant adverse effects?

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application